胰高血糖素样肽1受体激动剂（glucagon-like peptide-1 receptor agonist，GLP-1RA）是近年来2型糖尿病药物开发领域的研究热点。作为一种降血糖药物，GLP-1RA在增强患者血糖调控能力的同时，还能降低患者低血糖风险，减轻体重，保护心血管系统。此文对已上市和部分正处于临床试验阶段的GLP-1RA的疗效及安全性做一综述，并对GLP-1RA药物的发展趋势进行探讨。

Glucagon-like peptide-1 receptor agonist (GLP-1RA) has become an important therapeutic approach for type 2 diabetes. Evidence suggests that GLP-1RA can improve glycemic control while decrease risk of hypoglycemia, reduce body weight, and protecting cardiovascular system. This review presents the efficacy and tolerability of various GLP-1RA drugs available for clinical practice or under clinical trials, and concludes that optimized usage of GLP-1RA drugs could represent a significant paradigm shift for the treatment of type 2 diabetes.